Cardiomyopathies in China: A 2018-2019 state-of-the-art review.
Cardiomyopathies in China: A 2018-2019 state-of-the-art review.
复制标题
DOI：
10.1016/j.cdtm.2020.05.006
复制
发表时间：
2020-12
影响因子：
--
通讯作者：
Zhang SY
中科院分区：
文献类型：
--
作者：
Hua TR;Zhang SY
心肌病是心肌疾病，通常以心室扩张、肥大和心律失常为特征。患有心肌病的患者经常经历猝死和心力衰竭，并且在疾病进展过程中需要心脏移植。早期诊断、鉴别诊断和遗传咨询依赖于成像技术、基因检测和新兴的诊断工具，如血清生物标志物。近年来，心肌病的分子遗传学研究得到了广泛的关注。心肌病表型的异质性和重叠的潜在机制的发现揭示了疾病修饰剂的存在，这导致了新的疾病修饰疗法的出现。这篇2018-2019年的最新综述概述了中国心肌病的发病机制、诊断和治疗。
Cardiomyopathies are diseases of the cardiac muscle and are often characterized by ventricular dilation, hypertrophy, and cardiac arrhythmia. Patients with cardiomyopathies often experience sudden death and cardiac failure and require cardiac transplantation during the course of disease progression. Early diagnosis, differential diagnosis, and genetic consultation depend on imaging techniques, genetic testing, and new emerging diagnostic tools such as serum biomarkers. The molecular genetics of cardiomyopathies has been widely studied recently. The discovery of mechanisms underlying heterogeneity and overlapping of the phenotypes of cardiomyopathies has revealed the existence of disease modifiers, and this has led to the emergence of novel disease-modifying therapy. This 2018–2019 state-of-the-art review outlines the pathogenesis, diagnosis, and treatment of cardiomyopathies in China.